非编码RNA在乳腺癌化疗耐药中作用的研究进展

doi:10.11904/j.issn.1002-3070.2023.05.012

Abstract

Abstract: Breast cancer is a kind of malignant tumor with high heterogeneity.Chemotherapy is one of the important treatments for advanced breast cancer or postoperative breast cancer.However,the emergence of secondary drug resistance weakens the effectiveness of chemotherapy,leading to a poor prognosis for patients.In recent years,more and more studies have shown that non-coding RNA(ncRNA)can promote breast cancer chemotherapy resistance by regulating cell proliferation,tumor stem cell characteristics,epithelial-mesenchymal transition and other processes.This article reviews the research on the mechanism of ncRNA-mediated chemotherapy resistance in breast cancer.

Key words: Breast cancer, Non-coding RNA, Chemotherapy resistance

CLC Number:

R737.9

WANG Xinping, ZHANG Ziyun, WANG Xuedong. Research progress on the roles of non-coding RNA in chemotherapy resistance of breast cancer[J]. Journal of Practical Oncology, 2023, 37(5): 454-458.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2023.05.012

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2023/V37/I5/454

References

1 Yousefi H,Maheronnaghsh M,Molaei F,et al.Long noncoding RNAs and exosomal lncRNAs:classification,and mechanisms in breast cancer metastasis and drug resistance[J].Oncogene,2020,39(5):953-974.
2 Zhang L,Xu X,Su X.Noncoding RNAs in cancer immunity:functions,regulatory mechanisms,and clinical application[J].Mol Cancer,2020,19(1):48.
3 Ambros V.The functions of animal microRNAs[J].Nature,2004,431(7006):350-355.
4 Ponting CP,Oliver PL,Reik W.Evolution and functions of long noncoding RNAs[J].Cell,2009,136(4):629-641.
5 Saaoud F,Drummer IVC,Shao Y,et al.Circular RNAs are a novel type of non-coding RNAs in ROS regulation,cardiovascular metabolic inflammations and cancers[J].Pharmacol Ther,2021,220:107715.
6 Li H,Sun X,Li J,et al.Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1α/miR-494/survivin signaling pathway[J].Neoplasia,2022,32.
7 Yang Q,Zhao S,Shi Z,et al.Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling[J].J Exp Clin Cancer Res,2021,40(1):120.
8 Yang W,Gu J,Wang X,et al.Inhibition of circular RNA CDR1as increases chemosensitivity of 5-FU-resistant BC cells through up-regulating miR-7[J].J Cell Mol Med,2019,23(5):3166-3177.
9 Sabatier R,Charafe-Jauffret E,Pierga JY,et al.Stem cells inhibition by bevacizumab in combination with neoadjuvant chemotherapy for breast cancer[J].J Clin Med,2019,8(5):612.
10 Zhang Z,Qiu N,Yin J,et al.SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression[J].Theranostics,2020,10(10):4290-4307.
11 Han X,Li M,Xu J,et al.miR-1275 targets MDK/AKT signaling to inhibit breast cancer chemoresistance by lessening the properties of cancer stem cells[J].Int J Biol Sci,2023,19(1):89-103.
12 Cheng S,Huang Y,Lou C,et al.FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation[J].Cancer Biol Ther,2019,20(3):328-337.
13 Singh D,Assaraf YG,Gacche RN.Long non-coding RNA mediated drug resistance in breast cancer[J].Drug Resist Updat,2022,63:100851.
14 Armada A,Gomes BC,Viveiros M,et al.Regulation of ABCB1 activity by microRNA-200c and microRNA-203a in breast cancer cells:the quest for microRNAs' involvement in cancer drug resistance[J].Cancer Drug Resist,2019,2(3):897-911.
15 Xie M,Fu Z,Cao J,et al.MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer[J].Biomed Pharmacother,2018,102:286-294.
16 Chen Z,Pan T,Jiang D,et al.The lncRNA-GAS5/miR-221-3p/DKK2 axis modulates ABCB1-mediated ariamycin resistance of breast cancer via the Wnt/β-Catenin signaling pathway[J].Mol Ther Nucleic Acids,2020,19:1434-1448.
17 Wang R,Zhang T,Yang Z,et al.Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1[J].J Cell Mol Med,2018,22(9):4068-4075.
18 Tang W,Lu G,Ji Y,et al.Long non-coding RNA PCAT1 sponges miR-134-3p to regulate PITX2 expression in breast cancer[J].Mol Med Rep,2022,25(3):75.
19 Qiao Y,Jin T,Guan S,et al.Long non-coding RNA Lnc-408 promotes invasion and metastasis of breast cancer cell by regulating LIMK1[J].Oncogene,2021,40(24):4198-4213.
20 Zhu M,Wang F,Mi H,et al.Long noncoding RNA MEG3 suppresses cell proliferation,migration and invasion,induces apoptosis and paclitaxel-resistance via miR-4513/PBLD axis in breast cancer cells[J].Cell Cycle,2020,19(23):3277-3288.
21 Zhu L,Wang F,Fan W,et al.LncRNA NEAT1 promotes the taxol resistance of breast cancer via sponging the miR-23a-3p-FOXA1 axis[J].Acta Biochim Biophys Sin(Shanghai),2021,53(9):1198-1206.
22 白仲虎,李璐,戴晓峰.转录因子FOXA1在乳腺癌分子分型中的功能研究[J].生物学杂志,2017,34(1):6.
23 Venkatesh J,Wasson M,Brown J,et al.LncRNA-miRNA axes in breast cancer:novel points of interaction for strategic attack[J].Cancer Lett,2021,509:81-88.
24 Hashemi M,Arani HZ,Orouei S,et al.EMT mechanism in breast cancer metastasis and drug resistance:revisiting molecular interactions and biological functions[J].Biomed Pharmacother,2022,155:113774.
25 Tang L,Chen Y,Chen H,et al.DCST1-AS1 promotes TGF-β-Induced epithelial–mesenchymal transition and enhances chemoresistance in triple-negative breast cancer cells via ANXA1[J].Front Oncol,2020,10:280.
26 Ding J,Wu W,Yang J,et al.Long non-coding RNA MIF-AS1 promotes breast cancer cell proliferation,migration and EMT process through regulating miR-1249-3p/HOXB8 axis[J].Pathol Res Pract,2019,215(7):152376.
27 Saxena M,Hisano M,Neutzner M,et al.The long non-coding RNA ET-20 mediates EMT by impairing desmosomes in breast cancer cells[J].J Cell Sci,2021,134(21):jcs258418.
28 Poursheikhani A,Bahmanpour Z,Razmara E,et al.Non-coding RNAs underlying chemoresistance in gastric cancer[J].Cell Oncol(Dordr),2020,43(6):961-988.
29 Ma L,Zong X.Metabolic symbiosis in chemoresistance:refocusing the role of aerobic glycolysis[J].Front Oncol,2020,10:5.
30 Ma J,Zhao W,Zhang H,et al.Long non-coding RNA ANRIL promotes chemoresistance in triple-negative breast cancer via enhancing aerobic glycolysis[J].Life Sci,2022,306:120810.
31 Orre C,Dieu X,Guillon J,et al.The long non-coding RNA SAMMSON is a regulator of chemosensitivity and metabolic orientation in MCF-7 doxorubicin-resistant breast cancer Cells[J].Biology(Basel),2021,10(11):1156.
32 Wu M,Wen L,Zhou Y,et al.Role of lncRNA AGAP2-AS1 in breast cancer cell resistance to apoptosis by the regulation of MTA1 promoter activity[J].Technol Cancer Res Treat,2022,21:15330338221085360.
33 Zong B,Sun L,Peng Y,et al.HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance[J].Oncol Rep,2021,46(1):138.
34 Sunagawa Y,Yamada S,Sonohara F,et al.Genome-wide identification and characterization of circular RNA in resected hepatocellular carcinoma and background liver tissue[J].Scientific Reports,2021,11(1):6016.
35 Zeng Y,Zhang J,Yue J,et al.The role of DACT family members in tumorigenesis and tumor progression[J].Int J Biol Sci,2022,18(11):4532-4544.
36 Huang S,Xie J,Lei S,et al.CircDUSP1 regulates tumor growth,metastasis,and paclitaxel sensitivity in triple‐negative breast cancer by targeting miR‐761/DACT2 signaling axis[J].Mol Carcinog,2023,62(4):450-463.
37 Zhu M,Wang Y,Wang F,et al.CircFBXL5 promotes the 5-FU resistance of breast cancer via modulating miR-216b/HMGA2 axis[J].Cancer Cell Int,2021,21(1):384.
38 Wang L,Yang X,Zhou F,et al.Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis[J].Bioengineered,2022,13(3):7197-7208.

[1]	XUE Yuting, MAO Xionghui, SUN Ji, YUAN Zhennan. The role of long-chain non-coding RNA LINC-PINT in drug sensitivity of hypoxia induced in head and neck squamous cell carcinoma through the Hippo/YAP signaling pathway [J]. Journal of Practical Oncology, 2023, 37(6): 466-471.
[2]	FENG Churan, CAO Jianzhao, CHEN Ziyin, ZHANG Daxin, LU Hailing. Research progress on radiation-induced cardiac injury in breast cancer and its preventive measures [J]. Journal of Practical Oncology, 2023, 37(6): 513-518.
[3]	ZHAO Shilu, PANG Da. Bioinformatics screening and analysis of prognostic genes in breast cancer [J]. Journal of Practical Oncology, 2023, 37(5): 422-428.
[4]	CHU Sitong, XU Qingyong. Research progress on immunotherapy resistance mechanisms of triple-negative breast cancer [J]. Journal of Practical Oncology, 2023, 37(5): 449-453.
[5]	LU Hongnan, XIA Bingshu, QIAO Kun, ZHANG Shiyuan, HUANG Yuanxi, LU Xiangshi. Relationship between GAS1,immunotherapy and drug sensitivity in breast cancer [J]. Journal of Practical Oncology, 2023, 37(4): 351-359.
[6]	CHEN Fei, WANG Ying, ZENG Chuanqin. Expression of B7-H4 in breast cancer tissues and its correlation with axillary lymph node metastasis in patients after neoadjuvant chemotherapy [J]. Journal of Practical Oncology, 2023, 37(4): 360-366.
[7]	LI Fucheng, JIA Siyuan, BA Yuling, LUO Danli, XIAO Min. Research progress of immune checkpoint inhibitors in neoadjuvant therapy of early breast cancer [J]. Journal of Practical Oncology, 2023, 37(4): 367-371.
[8]	MA Yanling, QIAN Liting, WEI Donghua, YIN Huiping, Zhang Juan, ZHANG Xiaopeng. Analysis of screening rate and influencing factors of high-risk population of breast cancer in Hefei city of Anhui province from 2014 to 2017 [J]. Journal of Practical Oncology, 2023, 37(3): 200-206.
[9]	SUI Shiyao, ZHENG Wei, YANG Zihan, PANG Da. LncRNA SNHG4 inhibits ferroptosis of breast cancer through EP300-SNHG4-GPX4 axis [J]. Journal of Practical Oncology, 2023, 37(3): 215-223.
[10]	ZHANG Qinghuai, HAN Ameng, YANG Sen, LI Xiumei, ZHAO Jianxin, ZHANG Yanqiu. A comparative study of five radiotherapy techniques for breast cancer patients after breast-conserving surgery [J]. Journal of Practical Oncology, 2023, 37(3): 224-229.
[11]	YANG Shuai, WANG Xinheng, WU Jiale, FU Zitong, WEI Bo, YANG Lingbing, XU Shouping. Research progress of single-cell sequencing technology in breast cancer [J]. Journal of Practical Oncology, 2023, 37(3): 287-292.
[12]	ZHANG Xin, WU Xianmei, LI Hong, LIU Xiaozhou, KONG Dewen, CHEN Zhuo. The disease burden of breast cancer attributed to metabolic risk factors in the Chinese female population,from 1990 to 2019 [J]. Journal of Practical Oncology, 2023, 37(2): 107-111.
[13]	LIU Xinxin, MA Xiyuan, MIU Meiqi, WANG Yuqing, CHEN Jing. Research progress on the role of IL-6 and its receptor in the treatment of breast cancer [J]. Journal of Practical Oncology, 2023, 37(2): 149-154.
[14]	FENG Chengtian, HUANG Furong, JIANG Yongdong. Research progress of lipid metabolism on the mechanism of drug resistance to trastuzumab therapy in breast cancer [J]. Journal of Practical Oncology, 2023, 37(2): 155-159.
[15]	ZHOU Xingan, SU Nite, WU Xu, DA Lintai, DELEHEI Bateer. Research progress of exosomal lncRNA in squamous cell carcinoma [J]. Journal of Practical Oncology, 2023, 37(2): 160-163.

Research progress on the roles of non-coding RNA in chemotherapy resistance of breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments